Search research articles
Contact Us
Filters
Showing results (101-110 of 134) with videos related to
Page
of 14
Sort By:
AIDS (London, England)
|
November 8, 2017
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
José M Gatell, Lambert Assoumou, Graeme Moyle, et al.
HIV Medicine
|
September 16, 2021
COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in England
Alison E Brown, Sara E Croxford, Sophie Nash, et al.
The Journal of Antimicrobial Chemotherapy
|
June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
Ana González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy
|
April 24, 2024
Cardiometabolic health in people with HIV: expert consensus review
Rachel L Batterham, Roger J Bedimo, Ricardo S Diaz, et al.
The Journal of Antimicrobial Chemotherapy
|
August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
Ana González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Research Square
|
March 24, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Aljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Biorxiv : the Preprint Server for Biology
|
February 23, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Aljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Nature Communications
|
October 6, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Aljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 14, 2019
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E Sax, Kristine M Erlandson, Jordan E Lake, et al.
Scientific Reports
|
November 4, 2023
Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1
Aljawharah Alrubayyi, Emma Touizer, Dan Hameiri-Bowen, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 134) with videos related to
Sort By:
Page
of 14
AIDS (London, England)
|
November 8, 2017
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
José M Gatell, Lambert Assoumou, Graeme Moyle, et al.
HIV Medicine
|
September 16, 2021
COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in England
Alison E Brown, Sara E Croxford, Sophie Nash, et al.
The Journal of Antimicrobial Chemotherapy
|
June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
Ana González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy
|
April 24, 2024
Cardiometabolic health in people with HIV: expert consensus review
Rachel L Batterham, Roger J Bedimo, Ricardo S Diaz, et al.
The Journal of Antimicrobial Chemotherapy
|
August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
Ana González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Research Square
|
March 24, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Aljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Biorxiv : the Preprint Server for Biology
|
February 23, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Aljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Nature Communications
|
October 6, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Aljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 14, 2019
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E Sax, Kristine M Erlandson, Jordan E Lake, et al.
Scientific Reports
|
November 4, 2023
Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1
Aljawharah Alrubayyi, Emma Touizer, Dan Hameiri-Bowen, et al.
Page
of 14